Public research university in Leeds, established 1874
The UN Environment Programme has published a report saying the world will likely exceed the Paris 1.5°C limit within the next few years. UNEP recommends an "overshoot, peak and decline" pathway that combines immediate, deep emissions cuts with carbon dioxide removal and stronger adaptation to return temperatures below 1.5°C over coming decades.
A University College London study finds blanket smartphone bans in English schools are seen as punitive by students, with potential negative consequences. The government has introduced a country-wide ban, while researchers warn that such policies may erode trust and fail to address online harms.
A round-up of recent cancer-related reports shows patients benefiting from clinical trials and rare misdiagnoses being corrected. From rectal cancer trials in the UK to cervical cancer misdiagnoses under review, readers are kept informed on treatment advances and patient experiences.
Amanda Knox’s Edinburgh Fringe show Cartwheel has drawn renewed attention and protest after Stephanie Kercher criticised it as normalising violence against women. Knox defends the piece as a personal, motherhood-focused account of surviving wrongful imprisonment. Fringe organisers emphasise freedom of expression, while petitions call for cancellation.
Milburn’s review calls for primary schools to flag Neet risk from the end of primary education, with welfare reform and better mental health support on the horizon as government seeks to reduce youth disengagement.
Amanda Knox’s Edinburgh Fringe show Cartwheel is attracting controversy as petitions against it gain signatures while audiences and critics weigh its value as a personal, defiant retelling of her case. Reviews vary, with supporters praising its honesty and detractors arguing it trivialises violence against women.
The FDA has approved daraxonrasib (Rasonque), a once-daily pill from Revolution Medicines, for adults with metastatic pancreatic cancer who have received prior therapy or cannot take combination chemotherapy. A 500‑patient trial has shown median survival of 13.2 months versus 6.7 months for chemotherapy; a 30‑day supply will cost about $39,800 and expanded access has already treated thousands.